Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases

[1]  M. Luster,et al.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Matthew S. Johnson,et al.  Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Sze,et al.  International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  T. Frenzel,et al.  Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays. , 2020, Cancer letters.

[5]  S. Möller,et al.  TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[6]  D. Sze,et al.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  E. Assenat,et al.  Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. , 2018, Journal of vascular and interventional radiology : JVIR.

[8]  C. Atreya,et al.  Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. , 2016, Journal of gastrointestinal oncology.

[9]  Marc Peeters,et al.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.

[10]  I. Astsaturov,et al.  Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer , 2014, British Journal of Cancer.

[11]  A. Kennedy.  Radioembolization of hepatic tumors. , 2014, Journal of gastrointestinal oncology.

[12]  E. Petre,et al.  Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. , 2014, Clinical colorectal cancer.

[13]  J. Prieto,et al.  Prognostic factors and prevention of radioembolization‐induced liver disease , 2013, Hepatology.

[14]  D. Sze,et al.  Safety of Repeated Yttrium-90 Radioembolization , 2013, CardioVascular and Interventional Radiology.

[15]  N. Sugimoto,et al.  TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2012, The Lancet. Oncology.

[16]  Daniel B. Brown,et al.  Hepatic Artery Dissection in a Patient on Bevacizumab Resulting in Pseudoaneurysm Formation , 2011, Seminars in interventional radiology.

[17]  E. Van Cutsem,et al.  Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Izzo,et al.  Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases , 2010, British Journal of Cancer.

[19]  Z. Fedorowicz,et al.  Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. , 2008, The Cochrane database of systematic reviews.

[20]  Richard Pazdur,et al.  Endpoints for assessing drug activity in clinical trials. , 2008, The oncologist.

[21]  Michael A. Choti,et al.  Surgical Therapy for Colorectal Metastases to the Liver , 2007, Journal of Gastrointestinal Surgery.

[22]  J. Geschwind,et al.  Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations , 2007, CardioVascular and Interventional Radiology.

[23]  J. Thrall,et al.  Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..